Tuberous Sclerosis Complex Clinical Trial
Official title:
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a genetic disease that leads to mental retardation in over 50% of patients, and to learning problems, behavioral problems, autism and epilepsy in up to 90% of patients. The underlying deficit of TSC, loss of inhibition of the mammalian target of rapamycin (mTOR) protein due to dysfunction of the tuberin/hamartin protein complex, can be rescued by everolimus. Everolimus has been registered as treatment for renal cell carcinoma and giant cell astrocytoma (SEGA). Evidence in human and animal studies suggests that mTOR inhibitors improve learning and development in patients with TSC.
Randomized double-blind placebo controlled intervention study in children with TSC between
age 4 and 15 years with an intelligence quotient (IQ) estimated <80 and/or special schooling
and/or autism spectrum disorder and/or learning disability requiring remedial teaching.
Patients are randomised to receive everolimus or placebo during a period of 12 months.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT02687633 -
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
|
N/A | |
| Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
| Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
| Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
| Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
| Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
| Recruiting |
NCT04987463 -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
|
Phase 2/Phase 3 | |
| Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
| Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
| Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
| Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
| Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
| Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
| Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
| Recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
| Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 | |
| Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|
||
| Recruiting |
NCT05534672 -
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
|
Phase 3 |